Activation of Yes-associated protein (YAP) improves mouse acute liver failure by alleviating ferroptosis / 细胞与分子免疫学杂志

Objective To investigate the effects of YAP on the occurrence and progression of acute liver failure by regulating the ferroptosis pathway and its underlying mechanism. Methods A total of 20 8-week-old C57BL/6 mice were randomly divided into four groups: a control group, an acute liver failure model group, a YAP agonist XMU-MP-1 treatment group and a YAP inhibitor verteporfin treatment group, five mice for each group. HE staining was used to observe the pathological changes of hepatic inflammation and necrosis. Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were detected by liver biochemistry. Iron (Fe), malondialdehyde (MDA), glutathione (GSH) determination kits were used to measure their levels in liver tissues of each group. The changes of hepatocyte mitochondrial in each group were observed by electron microscopy. Real time PCR and Western blot analysis were used to detect the mRNA and protein expressions of YAP, glutathione peroxidase 4 (GPX4) and 5-lipoxygenase (5-LOX). Results Compared with the control group, mice in the acute liver failure model group and the YAP inhibitor verteporfin treatment group showed severe liver tissue congestion with inflammatory cell infiltration and structural damage to hepatic lobules. Liver injury was alleviated in the XMU-MP-1 treatment group. With the occurrence of liver failure, plasma ALT and AST levels significantly increased, and liver function was improved in XMU-MP-1 treatment group. Electron microscopy showed that mitochondria in hepatocytes of mice with liver failure became smaller and bilayer membrane density increased, while mitochondria changes in the XMU-MP-1 group were alleviated. In addition, the acute liver failure model group showed an increase in Fe and MDA contents, decreased protein expressions of GPX4, and enhanced expression of 5-LOX, suggesting that ferroptosis was involved in acute liver failure in C57BL/6 mice. Ferroptosis was inhibited by activation of YAP. Conclusion Activation of YAP may ameliorate liver injury by inhibiting ferroptosis.

Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab / 浙江大学学报·医学版

OBJECTIVE@#To observe the clinical effect of plasma exchange and tocilizumab in treatment of patients with severe coronavirus disease 2019 (COVID-19).@*METHODS@#Six patients with severe COVID-19 admitted in First Affiliated Hospital of Bengbu Medical College from January 25 to February 25, 2020. Three patients were treated with plasma exchange and three patients were treated with tocilizumab. The effect on excessive inflammatory reaction of plasma exchange and tocilizumab was observed.@*RESULTS@#The C-reactive protein (CRP) and IL-6 levels were significantly decreased and the lymphocyte and prothrombin time were improved in 3 patients after treatment with plasma exchange; while inflammation level was not significantly decreased, and lymphocyte and prothrombin time did not improve in 3 patients treated with tocilizumab.@*CONCLUSIONS@#For severe COVID-19 patients with strong inflammatory reaction, plasma exchange may be preferred.

Application of human resource management in the management of clinical skill teaching team / 中国基层医药

Based on the development requirements of the Clinical Skills Teaching Center of modern hospitals and the needs of clinical practice teaching, the innovative human resource management model is applied to the management of the clinical skills teaching team of Bengbu Medical College, thereby promoting the fine teaching of the business in the new era.The construction of an excellent teaching team has achieved obvious initial results.This research analyzes specific management measures in combination with the actual situation, and aims to provide a reference for improving the quality of clinical skills teaching teams in Bengbu Medical College, and even promoting the reform and management of clinical skills teaching teams in the country.

Emergence of the pre C and YMDD mutations and its clinical significance during lamivudine treatment / 中华传染病杂志

Objective To explore pre C and YMDD motif mutant of hepatitis B virus during lamivudine therapy. Methods From five chronic hepatitis B patients with serum HBeAg seroconversion but HBV DNA positive by polymerase chain reaction(PCR) following lamivudine therapy, sequences of the pre C and P genes of hepatitis B virus were analyzed by direct PCR product sequencing methods. Results All the five patients were observed to have G to A variations at nucleotide 1896. However, such mutations were observed only in 2 of the 5 patients before HBeAg seroconversion emerged. Meanwhile YMDD mutations were found in all the five patients during lamivudine therapy three of which were M552I mutants, two were M552I associated with L528M. One of the five patients had no reaction to the therapy, four had HBV DNA breakthrough during therapy. Conclusions The mutants of pre C associated with YMDD mutations may arise in the patients with HBeAg seroconversion and positive HBV DNA during the treatment of lamivudine. HBV DNA should be detected in the patients with HBeAg seroconversion to exclude the pre C mutation.

Detection of YMDD mutation during lamivudine therapy by real time fluorimetry PCR / 中华检验医学杂志

Objective Setting up a method to detect YMDD mutation during lamivudine therapy. Methods Two specific fluorescent probes were designed, on the unpaired base can remarkably affect melting temperature when oligonucleotide probe binding to DNA template. 297 patients (354 sera samples) were detected YMDD mutation by real time fluorimetry PCR. Results 156 YMDD mutation were found in 354 sera samples (44.1%), in which the mixed variant species were 34%(53/156). In the same time, nine sera samples wre sequenced. The results of sequencing were fully corresponded to those of fluorimetry PCR. The statistical analysis showed that YMDD variants were obviously correlated with ALT level(P